KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arbutus Biopharma (ABUS) Shares Outstanding (2016 - 2025)

Arbutus Biopharma (ABUS) has disclosed Shares Outstanding for 16 consecutive years, with $192.5 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding rose 1.35% to $192.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $192.5 million through Dec 2025, up 1.35% year-over-year, with the annual reading at $192.5 million for FY2025, 1.35% up from the prior year.
  • Shares Outstanding hit $192.5 million in Q4 2025 for Arbutus Biopharma, roughly flat from $192.0 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $192.5 million in Q4 2025 to a low of $96.2 million in Q1 2021.
  • Historically, Shares Outstanding has averaged $162.1 million across 5 years, with a median of $167.3 million in 2023.
  • Biggest five-year swings in Shares Outstanding: tumbled 98.62% in 2021 and later surged 13019.56% in 2022.
  • Year by year, Shares Outstanding stood at $145.0 million in 2021, then rose by 8.6% to $157.5 million in 2022, then grew by 7.88% to $169.9 million in 2023, then grew by 11.83% to $190.0 million in 2024, then increased by 1.35% to $192.5 million in 2025.
  • Business Quant data shows Shares Outstanding for ABUS at $192.5 million in Q4 2025, $192.0 million in Q3 2025, and $191.6 million in Q2 2025.